Nivolumab (Opdivo)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses nivolumab (Opdivo); strength: 40 mg nivolumab/4 mL (10 mg/mL) and 100 mg nivolumab/10 mL (10 mg/mL); route of administration: IV infusion. Indication: Opdivo, as monotherapy, is indicated for the adjuvant treatment of adult patients with stage IIB or IIC melanoma following complete resection.